Incorporated in 1987, Vasundhara Rasayans Ltd is a manufacturer and exporter of Antacids
The company possesses a narrow moat based on its position as a specialized manufacturer of Antacid APIs, where regulatory compliance and technical customer support create moderate switching costs. However, the metric of net margins (12.4%) and ROCE (20.8%) are healthy but vulnerable to the price erosion and competitive entry mentioned in recent reports.
Management has focused on maintaining a debt-free balance sheet while deploying significant surplus funds into unsecured loans to the holding company (P&J Cretechem) rather than aggressive internal capacity expansion. Dividends are consistent at 20%, but the high volume of related-party lending raises questions about optimal capital use for minority shareholders.
The investment collapsed as the company's capital was systematically drained through unsecured loans to the holding company, leaving the core business starved of the plant revamps and storage expansion it desperately needed. When the anticipated price erosion in the antacid API market materialized, the company lacked the scale and efficiency to compete, and its precarious 3-month lease notice was triggered, forcing a costly relocation that wiped out the remaining equity value while cash remained trapped in related-party receivables.
RichFakir rates Vasundhara Rasayans Ltd's business quality as decent — 59/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Vasundhara Rasayans Ltd is trading about 68% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Vasundhara Rasayans Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Vasundhara Rasayans Ltd's fair value is about ₹403 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →